Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a nearly 12-year-old boy with alopecia universalis and atopic dermatitis experienced full hair regrowth and improved dermatitis following treatment with upadacitinib, a JAK 1 inhibitor, showing notable positive effects on his psychological well-being and family.

In this study, three patients with extensive alopecia areata receiving ustekinumab treatment showed significant hair regrowth and decreased inflammation over 20 weeks, suggesting potential targeted treatment for this condition.

This retrospective pilot study found that oral tofacitinib was more effective in treating alopecia areata than alopecia universalis, but relapses were common after treatment cessation.

This study observed that oral tofacitinib was reasonably well-tolerated but had limited efficacy in treating alopecia areata, with a clinical response seen in 41.4% of patients over six months.

This report presents a case of alopecia areata manifesting in a linear pattern, deviating from the typical presentation of sharply demarcated round patches.

This study found that alopecia areata was associated with an increased risk of hematological malignancies, particularly non-Hodgkin lymphoma, but not with solid malignancies, except in certain severe cases.

In this study, children with alopecia areata and comorbid atopic diseases experienced an earlier onset of the condition and were more likely to develop severe forms compared to those without atopy.

This retrospective study described the demographic characteristics, treatments, and prognosis of children with alopecia areata in a clinical setting, reporting a remission rate of 34.5% and highlighting the need for more comprehensive epidemiological data in this population.

This study observed that nearly 70% of children with treatment-resistant alopecia areata had nail involvement, and while this was associated with longer disease duration, it did not correlate with the severity of scalp hair loss.

In this retrospective study, researchers observed that alopecia areata manifests in various forms among Malagasy children and presents challenges in treatment, with mixed regrowth results following corticosteroid therapy and methotrexate.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

This study suggests that women with alopecia have decreased microcirculation oscillations, which may imply neuroinflammation as a factor in the disease's pathogenesis.

In this retrospective study, baricitinib effectively improved alopecia areata in 78.7% of patients by the end of treatment, with significant hair regrowth observed, particularly in those with disease duration of four years or less, and showed no serious adverse events.

In this study, patients with severe alopecia areata treated with baricitinib showed continued improvement in scalp hair regrowth from weeks 52 to 152, particularly among those initially responding with eyelash or eyebrow regrowth but not scalp hair, with 39% achieving substantial regrowth by week 104.

In this review, the authors noted that while baricitinib, a treatment for refractory rheumatoid arthritis and severe alopecia areata, shows promising efficacy, it may pose risks of serious infections and malignancy due to immune downregulation.

Topical minoxidil and anthralin work for patchy alopecia areata but not for alopecia totalis/universalis.

This study found that 308 nm excimer lamp therapy provides a good clinical response with fewer adverse effects for limited alopecia areata but is less effective for widespread hair loss like alopecia totalis.

This study found that Diphenylcyclopropenone (DCP) was effective for treating extensive alopecia areata in Thai patients, although a high relapse rate suggests maintenance therapy might be necessary.

This study found that low-dose intermittent corticosteroid therapy may be a successful and well-tolerated treatment option for patients with alopecia areata, including those with alopecia totalis and universalis.

This study observed that nearly 70% of children with treatment-resistant alopecia areata had nail involvement, predominantly pitting, which was significantly linked to longer disease duration but not the severity of scalp hair loss.

This meta-analysis found that patients with alopecia areata, particularly those with more extensive forms like alopecia totalis and universalis, may face a higher risk of cardiovascular disease, though no links were found with specific conditions like ischemic stroke or myocardial infarction.

This meta-analysis found that patients with alopecia areata, especially those with alopecia totalis or alopecia universalis, have an increased risk of cardiovascular disease, possibly due to shared immunological mechanisms and systemic inflammation. Further research is needed to confirm these findings and explore underlying mechanisms.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

This Cochrane Review protocol aims to evaluate the effectiveness and safety of various treatments for alopecia areata through a network meta-analysis, but no specific study findings are reported yet.

This study found that individualized homeopathic medicine can significantly improve outcomes in patients with alopecia areata, including complete hair regrowth and reduced SALT scores within 5 to 12 months, without relapse, and shows promise for alopecia universalis through targeted miasmatic and constitutional remedies.

This review discusses treatment strategies for alopecia areata, emphasizing current immunomodulation approaches but reports no new clinical results.

Bexarotene gel shows promise as a new treatment for alopecia areata.

This article reviews the influence of thyroid hormone on skin and hair health, emphasizing its role in epidermal homeostasis and hair growth, but reports no new experimental results.

This source describes a case where a patient with Crohn's disease experienced remission of alopecia universalis after a colectomy, suggesting that addressing the intestinal inflammatory source might influence autoimmune manifestations like hair loss.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.